SCHEMBL5772894

SCHEMBL5772894

Cc1ccc(S(=O)(=O)N2CCN(c3ncc(C(F)(F)F)cc3Cl)CC2)cc1CC(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.62
GCK P35557 1/20 0.54
KMT2A Q03164 6/20 0.53
MEN1 O00255 5/20 0.53
NAMPT P43490 1/20 0.53
SMN1; SMN2 Q16637 7/20 0.51
MAPT P10636 5/20 0.51
HTT P42858 3/20 0.51
HPGD P15428 2/20 0.51
ALDH1A1 P00352 6/20 0.50
NPSR1 Q6W5P4 4/20 0.50
LMNA P02545 3/20 0.50
GAA P10253 3/20 0.50
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
POLB P06746 1/20 0.47
USP2 O75604 1/20 0.47
RECQL P46063 1/20 0.47
SLC6A9 P48067 1/20 0.47
KCNH2 Q12809 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5745816 0.87 LMNA (0.45) HSD11B1KMT2AMEN1MAPTHTT
SCHEMBL5487074 0.85 KDM4E (0.59) GCKKMT2AMEN1SMN1; SMN2MAPT
SCHEMBL5773259 0.83 HSD11B1 (0.55) HSD11B1GCKKMT2AMEN1NAMPT
SCHEMBL6348135 0.82 KDM4E (0.66) GCKKMT2AMEN1SMN1; SMN2HTT
SCHEMBL5750293 0.82 PPARD (0.49) GCKKMT2AMEN1MAPTHTT
SCHEMBL5748224 0.82 HTT (0.52) HSD11B1GCKKMT2AMEN1HTT
SCHEMBL5770474 0.81 KDM4E (0.63) HSD11B1KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL5748144 0.81 ABL1 (0.50) HSD11B1KMT2AMEN1SMN1; SMN2MAPT
SCHEMBL5770088 0.81 HSD11B1 (0.66) HSD11B1
SCHEMBL3596669 0.80 HSD11B1 (0.76) HSD11B1GCKKMT2AMEN1NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD HSD11B1 668/4885GCK 175/4885KMT2A 2378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.